An interventional study of Cigarette Type Switching in Cigarette Smoking and Inflammatory Response, sponsored by Rosalind Franklin University of Medicine and Science. Recruiting at 1 site in United States. Open to participants aged 21 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Rosalind Franklin University of Medicine and Science · Not applicable, Interventional, and Basic science
This study will focus on examining the potential impact of menthol flavoring in cigarettes on biomarkers of systemic inflammation as a subclinical indicator of cardiovascular disease risk.
The goal of this study is to examine how switching from menthol (MC) to non-menthol (NMC) cigarette smoking may impact biomarkers of systemic inflammation, smoking behavior, and subjective responses related to smoking. MC smokers (N=68) will be recruited for a five-week study, with one-week of baseline of MC smoking (Phase 1), followed by four weeks of switching to study-provided, brand-matched NMCs (Phase 2). Biomarkers of systemic inflammation and tobacco exposure will be analyzed from blood samples before, during, and after switching for four weeks (baseline, week 1, week 3, and week 5). Ecological momentary assessment methods will also be gathered to measure patterns of smoking and smoking-related subjective responses (affect, craving).
475 studies on the registry are indexed under Cigarette Smoking; 86 are open to participants now.
This study's planned enrollment of 68 is below the median of 96 across 406 interventional studies indexed under Cigarette Smoking.
Browse Cigarette Smoking studies →Rosalind Franklin University of Medicine and Science is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Participants will be switched from smoking menthol cigarettes to non-menthol cigarettes
Other: Cigarette Type Switching
Participants will be switched from smoking menthol cigarettes to non-menthol cigarettes for a period of four weeks
high sensitivity C-reactive protein
from serum in mg/dL
Time frame: 4 weeks
Fibrinogen
from serum in mg/dL
Time frame: 4 weeks
Cytokine Panel 13
from serum in mg/dL
Time frame: 4 weeks
Blood pressure
systolic blood pressure and diastolic blood pressure, in mm Hg
Time frame: 4 weeks
Heart rate
beats per minute
Time frame: 4 weeks
Affect
Positive and Negative Affect Scale (PANAS)
Time frame: 4 weeks
Urge to smoke
Questionnaire on Smoking Urges-Brief (QSU)
Time frame: 4 weeks
Nicotine Dependence
Fagerström Test for Cigarette Dependence (FTCD)
Time frame: 4 weeks
Number of cigarettes smoked
Self-reported total number of menthol and non-menthol cigarettes smoked per day
Time frame: 4 weeks
CO level
in ppm
Time frame: 4 weeks
Started Mar 2024 (actual). Primary completion is estimated for Jun 2027, 39 months after the start.
Of 184 non-industry interventional studies with no phase under Cigarette Smoking, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's planned 39 months is above that.
Counting every sponsor, half of 191 studies reached it within 20 months; a quarter within 9 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rosalind Franklin University of Medicine and Science